

## Machine Learning for Healthcare 6.7930, HST.956

Lecture 5: Feb 23, 2023 Peter Szolovits (with many slides from David Sontag)





## Outline for today's class

- **1. Introduction to risk stratification**
- Case study: Early detection of Type 2 diabetes
   Encoding longitudinal structured health data
- 3. Framing as supervised learning problem
  - Deriving labels from EHR

## What is risk stratification?

 Separate a patient population into high-risk and low-risk of having an outcome

Predicting something in the future

- Coupled with interventions that target highrisk patients
- Goal is typically to reduce cost and improve patient outcomes



Preterm infant's risk of severe morbidity?



(Saria et al., Science Translational Medicine 2010)



Figure sources: https://www.drmani.com/heart-attack/ (top) https://www.emra.org/emresident/article/acute-mi-case-report/ (right) Does this patient need to be admitted to the coronary-care unit?



(Pozen et al., NEJM 1984)



Will this woman develop breast cancer in the next 5 years?

(Yala et al., Science Translational Medicine 2021)



David, your genetics are associated with a **typical likelihood** of developing type 2 diabetes.



	ETHNICITY	AUC	VALUE
	European		0.652
Based on data from 23andMe research participants, people of European descent with genetics like yours have an estimated <b>22% chance</b> of developing type 2 diabetes at some point <b>between</b> <b>the ages of 37 (your current age) and 80.</b>			0.603
		ino	0.638
2296	East Asian		0.609
	African		0.588
0%		<b>UNA</b> Deoxyribonucleic acid	
TYPICAL RANGE			

#### Summary

This report is based on a statistical model that estimates the likelihood of developing type 2 diabetes by looking at genetic variants at 1,244 places in your DNA. We identified these variants and created this model using data from more than 1,110,000 23andMe research participants of European descent.

(Source: 23andme. https://permalinks.23andme.com/pdf/23\_19-Type2Diabetes\_March2019.pdf)

# How does risk stratification differ from differential diagnosis?

Differential diagnosis	Risk stratification
Usually iterative/active	Usually passive
Often considers a large set of conditions	Often just one condition
Has to consider rare conditions (needs hybrid knowledge/ML approaches)	Often focuses on settings where there is enough training data

## Old vs. New

• Traditionally, risk stratification was based on simple scores using human-entered data

	0 Points	1 Po	1 Point 2 Points		Points totaled	
Activity (muscle tone)	Absent	Arms and legs flexed		Active movement		
Pulse	Absent	Below 100 bpm		Over 100 bpm		
Grimace (reflex irritability)	Flaccid	Some fle Extrem	xion of nities	Active motion (sneeze, cough, pull away)		
Appearance (skin color)	Blue, pale	Body pink, Extremities blue		Completely pink		
Respiration	Absent	Slow, irregular		Vigorous cry		
Severely depressed 0-3						
			Moderately depressed 4-6			
			Excellent condition 7-10			

#### APGAR SCORING SYSTEM

## Old vs. New

- Traditionally, risk stratification was based on simple scores using human-entered data
- Now, based on machine learning on highdimensional data
  - Fits more easily into workflow
  - Higher accuracy
  - Quicker to derive (can special case)
- But, ML approach comes with new challenges

   to be discussed

## So, what do we need?

- Specification of prediction time / index date
- A way of encoding the data we have on the patient
  - CNN for images
  - Bag of words for text document
  - Longitudinal structured data …
- A target, typically derived from the EHR
- Choice of appropriate supervised ML algorithm — Regression? Classification?

# Outline for today's class

- 1. Introduction to risk stratification
- 2. Case study: Early detection of Type 2 diabetes
  - Encoding longitudinal structured health data
- 3. Framing as supervised learning problem

– Deriving labels from EHR

[Razavian, Blecker, Schmidt, Smith-McLallen, Nigam, Sontag. Big Data. '16]

### Type 2 Diabetes: A Major public health challenge



\$245 billion: Total costs of diagnosed diabetes in the United States in 2012
 \$831 billion: Total fiscal year federal budget for healthcare in the United
 States in 2014

- CDC 2022 estimate:
  - 11.3% of adults: 28.7M diagnosed, 8.5M undiagnosed
- Racial disparities among adults (20+)
  - non-Hisp White: 7.5%
  - non-Hisp Asian: 9.2%
  - non-Hisp Black: 11.7%

- Hispanic: 12.5%
- Native American: 14.7%

## Type 2 Diabetes Can Be Prevented \*

Requirement for successful large scale prevention program:

- 1. Detect/reach truly at risk population
- 2. Improve the interventions
- 3. Lower the cost of intervention

<sup>\*</sup> Diabetes Prevention Program Research Group. "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin." The New England journal of medicine 346.6 (2002): 393.

## **Traditional Risk Prediction Models**

- Successful Examples
  - ARIC
  - KORA
  - FRAMINGHAM
  - AUSDRISC
  - FINDRISC
  - San Antonio Model
- Easy to ask/measure in the office, or for patients to do online
- Simple model: can calculate scores by hand



## **Population-Level Risk Stratification**

 Key idea: Use readily available administrative, utilization, and clinical data



Source for figure: http://www.mahesh-vc.com/blog/understanding-whos-paying-for-what-in-the-healthcare-industry

## **Population-Level Risk Stratification**

- Key idea: Use readily available administrative, utilization, and clinical data
- Machine learning will find surrogates for risk factors that would otherwise be missing
- Perform risk stratification at the population level millions of patients

## A Data-Driven approach on Longitudinal Data-Based Prediction

- Looking at individuals who got diabetes *today*, (compared to those who didn't)
  - Can we infer which variables in their record could have predicted their health outcome?



Risk Stratification from Structured Health Data Reading: Razavian N, Blecker S, Schmidt AM, Smith- McLallen A, Nigam S, Sontag D (2015) <u>Population-level prediction of type</u> 2 diabetes from claims data and analysis of risk factors. Big Data 3:4, 277–287, DOI: 10.1089/big.2015.0020.

## Administrative & Clinical Data





## Target = f(Baseline)

- How to represent Baseline and Target?
- What class of models do we consider for *f*?

# **Claims Data Characteristics**

- Sparse data
  - Vast coding spaces for diagnoses, symptoms, procedures, medications, labs
  - Most patients don't have most of these
- Visit-level temporality
  - Data collected only at interactions with the health care system; highly variable intervals
- Long-term dependencies
  - How to encode these? LSTM, bi-RNN, CNN, attention, ...

1.

• simpler trends

## Top diagnosis codes

				Disease	count
				719.47 Joint pain-ankle	28648
Disease	count	Disease	count	300.4 Dysthymic disorder	28530
401.1 Benign hypertension	447017	530.81 Esophageal reflux	121064	268.9 Vitamin D deficiency	
272.4 Hyperlipidemia NEC/NOS	382030	427.31 Atrial fibrillation	113798	NOS	28455
401.9 Hypertension NOS	372477	729.5 Pain in limb	112449	V72.81 Preop cardiovsclr	
250.00 DMII wo cmp nt st		414.01 Crnry athrscl natve vssl	104478	exam	27897
uncntr	339522	285.9 Anemia NOS	103351	724.3 Sciatica	27604
272.0 Pure hypercholesterolem	232671	786.50 Chest pain NOS	91999	787.91 Diarrhea	27424
272.2 Mixed hyperlipidemia	180015	599.0 Urin tract infection NOS	87982	V2.21 Supervis oth normal	
V72.31 Routine gyn examination	178709	V58.69 Long-term use meds		preg	27320
244.9 Hypothyroidism NOS	169829	NEC	85544	365.01 Opn angl brderIn lo	
780.79 Malaise and fatigue NEC	149797	496 Chr airway obstruct NEC	78585	risk	26033
V04.81 Vaccin for influenza	147858	477.9 Allergic rhinitis NOS	77963	379.21 Vitreous	
724.2 Lumbago	137345	414.00 Cor ath unsp vsl ntv/gft	75519	degeneration	25592
V76.12 Screen mammogram				424.1 Aortic valve disorder	25425
NEC	129445			616.10 Vaginitis NOS	24736
V70.0 Routine medical exam	127848			702.19 Other sborheic	
				keratosis	24453
				380.4 Impacted cerumen	24046

#### Out of 135K patients who had laboratory data

## Top lab test results

Lab test		Lab test		Lab test	
2160-0 Creatinine	1284737			770-8 Neutrophils/100	
3094-0 Urea nitrogen	1282344	2085-9 Cholesterol.in HDL	1155666	leukocytes	952089
2823-3 Potassium	1280812	718-7 Hemoglobin	1152726	731-0 Lymphocytes	943918
2345-7 Glucose	1299897	4544-3 Hematocrit	1147893	704-7 Basophils	863448
1742-6 Alanine		9830-1 Cholesterol.total/		711-2 Eosinophils	935710
aminotransferase	1187809	Cholesterol.in HDL	1037730	5905-5 Monocytes/100	
1920-8 Aspartate		33914-3 Glomerular		leukocytes	943764
aminotransferase	1187965	filtration rate/1.73 sq		706-2 Basophils/100	
2885-2 Protein	1277338	M.predicted	561309	leukocytes	863435
1751-7 Albumin	1274166	785-6 Frythrocyte mean		751-8 Neutrophils	943232
2093-3 Cholesterol	1268269	cornuscular hemoglohin	1070832	742-7 Monocytes	942978
2571-8 Triglyceride	1257751	6690-2 Leukocytes	1062980	713-8 Eosinophils/100	
13457-7 Cholesterol.in LDL	1241208	789-8 Erythrocytes	1062//5	leukocytes	933929
17861-6 Calcium	1165370		1002443	3016-3 Thyrotropin	891807
2951-2 Sodium	1167675	787-2 Erythrocyte mean		4548-4 Hemoglobin A1c/	
		corpuscular volume	1063665	Hemoglobin.total	527062

#### **Count of the test result (ever)**

# Encoding the longitudinal health data



- Is the value decreasing?
- Is the value fluctuating?

# Encoding the longitudinal health data



# There may be a varying amount of history per patient



# Encoding the longitudinal health data



How does this deal with missing data? What are its limitations?

### **Combining Multi-Modal Data**

ML approach



Figure 1: A visual representation of the data used. 1) *Numerical data*, including vitals and lab tests. The timestamp for each data point is rounded to the nearest hour, and hours with multiple measurements for a variable are assigned the average of those measurements. Each measurement is normalized according to the min and max for that var and each patient's data are zero-padded to the maximum stay length (240 hours). To fill in missing values, we forward-fill values for each patient, and mean-impute for any remaining missing values. 2) *Narrative data*, which consists of unstructured text notes. After preprocessing, LDA is used to obtain underlying topics and we then represent each note as a distribution over these topics. We forward-fill and aggregate these topic vectors across time, mean-imputing any values that are still missing. 3) *Static Data*, including variables recorded at admission such as sex, age, and ethnicity. Categorical variables such as ethnicity and ICU type are transformed into one-hot vectors containing each possible type. We replicate this data across time so that we are able to feed in this information at every timestep. We normalize numerical values and use forward-filling and imputation as before.

Suresh H, Hunt N, Johnson A, Celi LA, Szolovits P, Ghassemi M. Clinical intervention prediction and understanding with deep neural networks. In: mlhc2017 [Internet]. 2017. p. 1–16. Available from: <u>https://arxiv.org/abs/1705.08498</u>

# Alternative encoding using self-attention / transformers



Li et al., *BEHRT: Transformer for Electronic Health Records*, Scientific Reports '20 Kodialam et al., *Deep Contextual Clinical Prediction with Reverse Distillation*, AAAI '21

# The latter can make use of unsupervised learning of concept embeddings



# Outline for today's class

- 1. Introduction to risk stratification
- Case study: Early detection of Type 2 diabetes
   Encoding longitudinal structured health data

## 3. Framing as supervised learning problem

– Deriving labels from EHR

# Where do the labels come from?

Typical pipeline:

- Manually label several patients' data by "chart review"
- 2. A) Come up with a simple rule to automatically derive label for all patients, **or**

B) Use machine learning to get the labels themselves

#### Visualization of individual patient data is an important part of chart review



https://github.com/nyuvis/patient-viz https://github.com/BenGlicksberg/PatientExploreR T1DM Dx EMR NO T2DM Dx Rx T1DM Rx T2DM T2DM Dx YES-YESby physcn NOmed med >= 2 NO YES NO T2DM Rx Rx T2DM Rx T2DM precedes med med T1DM Rx YES YES YES Abnormal YES NO Lab YES CASE

Figure 1: Algorithm for identifying T2DM cases in the EMR.

Step 2: Example of a rule-based phenotype

(Northwestern U.)

Source: https://phekb.org/sites/phenotype/files/T2DM-algorithm.pdf

## Step 2: Example of a rule-based phenotype

Coverage of Different Diabetes Outcome Definitions on Claims Data

Condition	Percentage
Here 250 v diagnosis, er here heen en diehetie mediestien, er here	
Have 250.x diagnosis, or have been on diabetic medication, or have	
any HbA1c $\geq$ 6.5	100 %
Have been diagnosed 250.xx	89.9 %
Have been on diabetic medications	15.0 %
Have HbA1c values ≥ 6.5	20.9 %
Have 250.xx diagnosis on more than one distinct date	40.0 %
(Have 250.xx diagnosis, or have been on diabetic medication, or	
have any HbA1c $\geq$ 6.5) on more than one distinct date	44.0 %
(Have 250.xx diagnosis, or have been on diabetic medication, or	<i>A</i> 110/
nave any HDAIC 2 6.5) on two dates separated by at least a week	41.1 %
The second state of the second state of the first state of the second state of the sec	Definition coloct

The earliest date the rule triggers is defined as the date of diabetes diagnosis

Definition selected

[Razavian, Blecker, Schmidt, Smith-McLallen, Nigam, Sontag. Big Data. '16]

Step 2: Example of a rule-based phenotype

Login Request Account PheK a knowledgebase for discovering phenotypes from electronic medical records Search Home Phenotypes Resources Contact Us ᢙ Public Phenotypes Public Collaboration Public phenotypes are believed to be complete and final by their authors. When you are logged in you can view and edit phenotypes in your groups that are non public and in various stages of development. Login To View Private Group Phenotypes Institution Type of Phenotype Owner Phenotyping Groups View Phenotyping Groups Þ Disease or Syndrome • Data Model Apply - Any **Data Modalities** Owner Has Title Institution and Methods Phenotyping View Groups new Status Type Used Groups content eMERGE Geisinger eMERGE Disease Abdominal Aortic CPT Codes, ICD 9 Group, 20 Final Geisinger Geisinger or Aneurysm (AAA) Codes, Vital Signs eMERGE Group Syndrome Phenotype WG ICD 9 Codes, eMERGE Disease ADHD phenotype eMERGE Medications CHOP Phenotype Final or algorithm Natural Language CHOP Group WG Syndrome Processing CPT Codes, ICD 9 eMERGE eMERGE Disease Codes, Cincinnati Children's Hospital Appendicitis Medications, CCHMC/BCH Phenotype Final or Medical Center Natural Language WG Group Syndrome Processing CPT Codes, ICD 9 Vanderbilt -Disease Atrial Fibrillation -Vanderbilt -Codes, Natural SD/RD Vanderbilt University Final or Demonstration Project Language SD/RD Group Group Syndrome Processing ICD 9 Codes, eMERGE eMERGE Disease Cincinnati Children's Hospital Medications, Autism 3 CCHMC/BCH Phenotype Final or Medical Center Natural Language WG Syndrome Group Processing CPT Codes, ICD 9 eMERGE eMERGE Disease Codes. Marshfield Clinic Research Cataracts Medications. Marshfield Phenotype Final or Foundation Natural Language Group WG Syndrome Processing ICD 9 Codes Vanderbilt Disease Vanderbilt -Crohn's Disease -Medications,

☆

Q 🛆 

https://www.phekb.org/phenotypes?field\_pgx\_type\_tid\_1=398&field\_data\_model\_value=All

00



### Exclusion criteria:

- Diabetes diagnosis (according to our rule) observed prior to January 1, 2009
- Less than 6 months of enrollment in feature construction window
- Member left health insurance prior to Jan. 1, 2011
   What if someone is diagnosed with diabetes in 2012?
   Why not model as "patient develops diabetes anytime after 2009"?

[Razavian, Blecker, Schmidt, Smith-McLallen, Nigam, Sontag. Big Data. '16]



### Exclusion criteria:

- Diabetes diagnosis (according to our rule) observed prior to January 1, <del>2009</del> 2011
- Less than 6 months of enrollment in feature construction window
- Member left health insurance prior to Jan. 1, <del>2011</del> 2013

[Razavian, Blecker, Schmidt, Smith-McLallen, Nigam, Sontag. Big Data. '16]



- Suppose we want to run the above model in August 2009. It may not have good performance due to *non-stationarity* in the data
- We now have data through 2021. Using a fixed prediction time / index date of Jan. 1, 2009 is ignoring most of the diabetes onsets!

• We can instead create *many* data points from each patient, using e.g. every month as an index date:



• Important: If multiple data points per patient, make sure each patient's data is in *only* train, validate, or test